Skip to main content

Drug Interactions between chikungunya vaccine, recombinant (cvx 329) and etrasimod

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

etrasimod chikungunya vaccine, recombinant (cvx 329)

Applies to: etrasimod and chikungunya vaccine, recombinant (cvx 329)

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: The administration of inactivated, killed, or otherwise noninfectious vaccines during etrasimod therapy has not been studied but may be associated with a diminished or suboptimal immunologic response. Vaccination may be less effective if administered during and for up to 5 weeks after discontinuation of etrasimod therapy.

MANAGEMENT: According to some authorities, the immune response to vaccines may be reduced during and for at least 2 weeks after discontinuation of etrasimod therapy. In patients who have recently been vaccinated, etrasimod therapy should preferably be postponed for at least one month to allow the full effect of vaccination to occur.

Drug and food interactions

Moderate

etrasimod food

Applies to: etrasimod

Grapefruit juice may increase the blood levels of etrasimod. You should avoid grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with etrasimod unless directed otherwise by your doctor. Talk to your doctor if you have any questions or concerns. Contact your doctor if your condition changes or you experience increased side effects, such as fever, high temperature or flu-like symptoms, severe headache, confusion, seizures, dizziness, tiredness, lightheadedness, chest pain, shortness of breath, or irregular or abnormal heartbeat, blurriness or shadows in the center of your vision, and nausea, vomiting, abdominal pain, anorexia, or jaundice and/or dark urine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer